04-12-01

PTO/SB/05 (11-00)
Please type a plus sign (+) inside this box

Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

## UTILITY **PATENT APPLICATION TRANSMITTAL**

A064 US Attorney Docket No. Whitty First Inventor Interferon-Beta Fusion Proteins and Uses

Express Mail Label No. E1-475127505US

	inal applications under or of it 1.55()	-//	orcas iviali Label IVO.		
	ATION ELEMENTS		ADDDECC TA.	Assistant Commiss Box Patent Applica	
	cerning utility patent application cont	ents.		Washington, DC 2	0231
Fee Transmittal F (Submit an original and of Applicant claims See 37 CFR 1.27  3. Specification (preferred arrangeme) - Descriptive title - Cross Reference - Statement Reg - Reference to so or a computer - Background of - Brief Summary	Form (e.g., PTO/SB/17) a duplicate for fee processing) small entity status.  [Total Pages 63 ] et of the invention be to Related Applications parding Fed sponsored R & D equence listing, a table, program listing appendix ithe Invention of the Invention of the Drawings (if filed) iption  Disclosure		7. CD-ROM or CD-Computer Progr 8. Nucleotide and/or Amin (if applicable, all neces a. Computer Rea b. Specification Seque i. CD-RO ii. paper c. Statements ve  ACCOMPANYIN 9. Assignment Pa 10. (when there is.)	R in duplicate, largam (Appendix) to Acid Sequence sary) dable Form (CRF) nce Listing on: M or CD-R (2 copid rifying identity of all pers (cover sheet 8) Statement	ge table or Submission es); or bove copies ON PARTS & document(s)) Power of Attorney
0()(		 	Information Dis	·	Copies of IDS
b. Copy from a (for continue i. DELET Signed stanamed in 1.63(d)(2)  6. Application Data  18. If a CONTINUING APPL or in an Application Data Show Prior application information  For CONTINUATION OR DIVIS  Box 5b, is considered a part of	Newly executed (original or copy) Copy from a prior application (37 CFR 1.63 (d)) (for continuationIdivisional with Box 18 completed)  i. DELETION OF INVENTOR(S) Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b)  Application Data Sheet. See 37 CFR 1.76  CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment,  Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation Divisional Continuation Examiner Freiminary Amendment  14.  Return Receipt Postcard (MPEP 503) (Should be specifically itemized)  15. Certified Copy of Priority Document(s) (if foreign priority is claimed)  16. Request and Certification under 35 U.S.C. 122 (b)(2)(B)(i). Applicant must attach form PTO/SB/35 or its equivalent 17.  Other:  CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, Application Data Sheet under 37 CFR 1.76: Continuation Divisional Continuation Divisional Continuation Examiner From Application No.: PCT/US00/24200  Group Art Unit: Group Art Unit: From Application and is hereby incorporated by reference. Divisional application and is hereby incorporated by reference. Divisional application parts.  19. CORRESPONDENCE ADDRESS				
Name	Raymond G. Arner	TURNITUS.			
Hamo	BIOGEN, INC.				
	14 Cambridge Center	·	744		
Address					
City	Cambridge	Stat	e MA	Zip Code	02142
Country	USA	Telephor	ne (617) 679-285	7 Fax	(617) 679-2838
Name (Print/Type) Signature	Raymond G. Arner		Registration No. (Attor	<del></del>	32,958 April 2001

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO. Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231. Washington, DC 20231.

PTO/SB/17 (09-00)
Approved for use through 10/31/2002. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to re-

## **FEE TRANSMITTAL** for FY 2001

Patent fees are subject to annual revision.

TOTAL	AMOUNT	OF F	AYMENT

2.2

(\$)	1,2	32
------	-----	----

espond to a collection of information u	<u>nless it displays a valid OMB control numb</u> er
Complete	if Known
Application Number	
Filing Date	
First Named Inventor	Whitty
Examiner Name	
Group Art Unit	
Attorney Docket No.	A064 US

METHOD OF PAYMENT	FEE CALCULATION (continued)			
The Commissioner is hereby authorized to charge indicated foce and oradit any overseyments to	3. ADDITIONAL FEES			
Deposit Deposit	Large Entity Small Entity Fee			
Account Number BIOGEN, INC.	Code (\$) Code (\$) Fee Description Fee Pa	iid		
Deposit	105 130 205 65 Surcharge - late filing fee or oath	$\exists$		
Account Name 02-2327	127 50 227 25 Surcharge - late provisional filing fee or cover sheet	_		
Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17	139 130 139 130 Non-English specification	_		
Applicant claims small entity status	147 2,520 147 2,520 For filing a request for ex parte reexamination	_		
See 37 CFR 1 27  2. Payment Enclosed:	112 920* 112 920* Requesting publication of SIR prior to Examiner action	$\Box$		
Check Credit card Money Other	113 1,840* 113 1,840* Requesting publication of SIR after Examiner action			
FEE CALCULATION	115 110 215 55 Extension for reply within first month	_		
1. BASIC FILING FEE	116 390 216 195 Extension for reply within second month			
Large Entity Small Entity	117 890 217 445 Extension for reply within third month			
Fee Fee Fee Fee Description	118 1,390 218 695 Extension for reply within fourth month	_		
101 710 201 255 Hellity Sline for	128 1,890 228 945 Extension for reply within fifth month			
106 320 206 160 Design filing fee 710	119 310 219 155 Notice of Appeal	$\Box$		
107 490 207 245 Plant filing fee	120 310 220 155 Filing a brief in support of an appeal			
108 710 208 355 Reissue filing fee	121 270 221 135 Request for oral hearing			
114 150 214 75 Provisional filing fee	138 1,510 138 1,510 Petition to institute a public use proceeding	$\Box$		
	140 110 240 55 Petition to revive - unavoidable	_		
SUBTOTAL (1) (\$) 710	141 1,240 241 620 Petition to revive - unintentional			
2. EXTRA CLAIM FEES	142 1,240 242 620 Utility issue fee (or reissue)			
Fee from Ext <u>ra Claims below</u> Fee Paid	143 440 243 220 Design issue fee			
Total Claims 34 -20** = 14 X 18 = 252 Independent 3 2** - 0 X	144 600 244 300 Plant issue fee	$\Box$		
Claims S - C X = C C X	122 130 122 130 Petitions to the Commissioner	$\Box$		
Multiple Dependent 270 = 270	123 50 123 50 Petitions related to provisional applications	_		
Large Entity Carell Factor	126 240 126 240 Submission of Information Disclosure Stmt	$\dashv$		
Large Entity Small Entity Fee Fee Fee Fee Description Code (\$) Code (\$)	581 40 581 40 Recording each patent assignment per property (times number of properties)			
103 18 203 9 Claims in excess of 20	146 710 246 355 Filing a submission after final rejection (37 CFR § 1.129(a))	1		
102 80 202 40 Independent claims in excess of 3  104 270 204 135 Multiple dependent claim, if not paid	149 710 249 355 For each additional invention to be	٦		
109 80 209 40 ** Reissue independent claims	examined (37 CFR § 1.129(b))  179 710 279 355 Request for Continued Examination (RCE)	$\exists$		
over original patent  110 18 210 9 ** Reissue claims in excess of 20	169 900 169 900 Request for expedited examination	٦		
and over original patent	of a design application	4		
SUBTOTAL (2) (\$) 522	Other fee (specify)	_		
**or number previously paid, if greater, For Reissues, see above	Reduced by Basic Filing Fee Paid SUBTOTAL (3) (\$) 0			
SUBMITTED BY Complete (if applicable)				
Name (PrintiType) Raymond G. Arger	Registration No. 22.059 Telephone (617) 670, 2057			
Signature	(Attorney/Agent) 32,938 relephone (617) 6/9-2857			

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

ERTIFICATE OF In plicant(s): Whitty, et	MAILING BY "EXPRESS I al.	MAIL" (37 CFR 1.10)	Docket No. A064 US
Serial No. not assigned yet	Filing Date herewith	Examiner	Group Art Unit
ention: Interferon-Bo	eta Fusion Proteins and Uses		Jesus U. s. 09/832659
Applica	s <u>Utility and Fee Transmittals,</u> ation and Power, ation and drawings h the United States Postal Servi	sequence (statement, copy and (Identify type of correspondence)	
-	velope addressed to: The Assista		
<b>+</b>		Patricia Ho (Typed or Printed Name of Person (Signature of Person Mailin EL4751275	Mailing Correspondence)  Grant Correspondence)  505US
		,,	,
	Note: Each paper must h	ave its own certificate of mailing.	

P06A/REV02

Copyright 1995 Legalsoft